This study is currently not recruiting participants.

An Open-Label Multicenter Study to Evaluate the Pharmacokinetics Safety and Efficacy of Ombitasvir (OBV) Paritaprevir (PTV) Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)

Study on Investigational Medication for Hepatitis C in Children

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to determine drug doses for children and to see if the study drugs are safe and able to reduce the amount of hepatitis C virus in the blood.

Detailed description of study

The purpose of this study is to determine drug doses for children and to see if the study drugs are safe and able to reduce the amount of hepatitis C virus in the blood.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: hepatitis C
  • Age: 100 years or below
  • Gender: All

The purpose of this study is to investigate the safety and effectiveness of an investigational medication for children with hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus, which can lead to serious liver damage over time.

Participants in the study will receive different doses of the investigational medication to find the safest and most effective dose. The study will monitor the amount of hepatitis C virus in the blood to see how well the medication works.

  • Who can participate: The study is seeking children aged X to Y diagnosed with hepatitis C.
  • Study details: Participants will receive different doses of an investigational medication to determine the safest and most effective dose. A placebo, an inactive substance that looks like the investigational medication but does not contain any medicine, may be used for comparison.
Updated on 19 Feb 2024. Study ID: 1510378388

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team